Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNF185 control of COL3A1 expression impacts prostate cancer migration and metastatic potential

ABSTRACT: RNF185 is a RING finger domain-containing ubiquitin ligase implicated in ER associated degradation. Analysis of prostate tumor patient data revealed a negative correlation between RNF185 expression and prostate cancer progression and metastasis. Likewise, several prostate cancer cell lines exhibited greater migration and invasion capabilities in culture, upon RNF185 depletion. Subcutaneous inoculation of mouse prostate cancer MPC3 cells that stably express shRNA against RNF185 into B6 mice, resulted in larger tumors and more frequent lung metastases. RNA-sequencing and Ingenuity Pathway Analysis identified wound healing and cellular movement among the most significantly upregulated pathways in RNF185-depleted prostate cancer cells, compared with control. Gene Set Enrichment Analyses that were performed in both patients harboring low RNF185 expression, and in RNF185-depleted cell lines, confirmed deregulation of genes implicated in EMT. Among those, COL3A1 was identified as the primary mediator of RNF185 ability to impact the migration phenotype. Correspondingly, enhanced migration of RNF185 KD prostate cancer cells was abolished upon COL3A1 inhibition. Taken together, our results identify RNF185 as gatekeeper of prostate cancer metastasis, in part by its control of COL3A1 transcription.

ORGANISM(S): Mus musculus

PROVIDER: GSE228999 | GEO | 2024/02/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential.

Project description:RNF185 is a RING finger domain-containing ubiquitin ligase implicated in ER-associated degradation. Prostate tumor patient data analysis revealed a negative correlation between RNF185 expression and prostate cancer progression and metastasis. Likewise, several prostate cancer cell lines exhibited greater migration and invasion capabilities in culture upon RNF185 depletion. Subcutaneous inoculation of mouse prostate cancer MPC3 cells stably expressing shRNA against RNF185 into mice resulted in larger tumors and more frequent lung metastases.RNA-sequencing and Ingenuity Pathway Analysis identified wound healing and cellular movement among the most significant pathways upregulated in RNF185-depleted, compared to control prostate cancer cells. Gene Set Enrichment Analyses performed in samples from patients harboring low RNF185 expression and in RNF185-depleted lines confirmed the deregulation of genes implicated in EMT. Among those, COL3A1 was identified as the primary mediator of RNF185’s ability to impact migration phenotypes. Correspondingly, enhanced migration and metastasis of RNF185 KD prostate cancer cells were attenuated upon co-inhibition of COL3A1. Our results identify RNF185 as a gatekeeper of prostate cancer metastasis, partly via its control of COL3A1 availability.

2024-08-09 | PXD045473 | Pride

RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential

Project description:RNF185 is a RING finger domain-containing ubiquitin ligase implicated in ER-associated degradation. Prostate tumor patient data analysis revealed a negative correlation between RNF185 expression and prostate cancer progression and metastasis. Likewise, several prostate cancer cell lines exhibited greater migration and invasion capabilities in culture upon RNF185 depletion. Subcutaneous inoculation of mouse prostate cancer MPC3 cells stably expressing shRNA against RNF185 into mice resulted in larger tumors and more frequent lung metastases. RNA-sequencing and Ingenuity Pathway Analysis identified wound healing and cellular movement among the most significant pathways upregulated in RNF185-depleted, compared to control prostate cancer cells. Gene Set Enrichment Analyses performed in samples from patients harboring low RNF185 expression and in RNF185- depleted lines confirmed the deregulation of genes implicated in EMT. Among those, COL3A1 was identified as the primary mediator of RNF185's ability to impact migration phenotypes. Correspondingly, enhanced migration and metastasis of RNF185 KD prostate cancer cells were attenuated upon coinhibition of COL3A1. Our results identify RNF185 as a gatekeeper of prostate cancer metastasis, partly via its control of COL3A1 availability.

2023-10-18 | GSE245708 | GEO

Human prostate cancer cell TUBB4A LC-MS

Project description:Human tubulin beta class IVa (TUBB4A) is a member of the β-tubulin family. In most normal tissues, expression of TUBB4A is little to none, but it is highly expressed in human prostate cancer. Here we show that high expression levels of TUBB4A are associated with aggressive prostate cancers and poor patient survival, especially for African-American men. Additionally, in prostate cancer cells, TUBB4A knockout (KO) reduces cell growth and migration but induces DNA damage through increased γH2AX and 53BP1. Furthermore, during constricted cell migration, TUBB4A interacts with MYH9 to protect the nucleus, but either TUBB4A KO or MYH9 knockdown leads to severe DNA damage and reduces the NF-κB signaling response. Also, TUBB4A KO retards tumor growth and metastasis. Functional analysis reveals that TUBB4A/GSK3β binds the N-terminal of MYH9, and TUBB4A KO reduces MYH9-mediated GSK3β ubiquitination and degradation, leading to increased activation of GSK3β/β-catenin signaling and to the epithelial-mesenchymal transition. Likewise, prostate-specific deletion of Tubb4a reduces spontaneous tumor growth and metastasis via inhibition of NF-κB, cyclin D1, and c-MYC signaling activation. Our results suggest an oncogenic role of TUBB4A and provide a potentially new actionable therapeutic target for prostate cancers with TUBB4A overexpression.

2022-06-09 | PXD033359 | Pride

Project description:RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential

| PRJNA1023976 | ENA

RNF185 control of COL3A1 expression impacts prostate cancer migration and metastatic potential

Project description:RNF185 control of COL3A1 expression impacts prostate cancer migration and metastatic potential

| PRJNA952534 | ENA

The Rac1/Cdc42 regulator CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis

Project description:The high mortality of prostate cancer (PCa) patients is primarily due to metastasis, which can be associated with castration-resistant PCa. Therefore, understanding the mechanisms controlling metastatic processes remains essential to improve the success of targeted therapies. The Rac1/Cdc42 regulator CdGAP (Cdc42 GTPase-activating protein) has been implicated in fundamental cellular processes involved during cancer progression. Here, we demonstrate that elevated CdGAP expression is associated with early biochemical relapse (BCR) and bone metastasis in PCa patients. Furthermore, gene expression analysis of CdGAP in PCa data sets revealed a positive association between high CdGAP expression and early BCR. CdGAP protein and mRNA levels were elevated in PC-3 cells with high metastatic potential compared to low levels of CdGAP in the androgen receptor positive LNCaP cell line. Knockdown of CdGAP in PC-3 cells reduced cell motility, invasion, proliferation and colony-formation ability while inducing an increase in cell apoptosis. Conversely, overexpression of CdGAP in DU-145 cells increased cell migration and invasion. Using global gene expression approaches we found that CdGAP regulates the expression of genes involved in EMT, apoptosis and cell cycle progression. Subcutaneous injection of CdGAP-depleted PC-3 cells into mice showed a delayed tumor initiation and attenuated tumor growth. Orthotopic prostate injection of CdGAP-depleted PC-3 cells reduced cancer metastasis to kidneys, bones, and testis. Collectively, these findings support a pro-oncogenic role of CdGAP in prostate tumorigenesis and unveil CdGAP as a novel biomarker and potential target for prostate cancer treatments.

2021-08-12 | GSE160399 | GEO

Lysine-specific demethylase 1 metastasis of androgen-independent PCa cells [RNA-seq]

Project description:The aim of this study is to identify the LSD1 target genes in metastatic androgen independent prostate cancer Lysine-specific demethylase 1 (LSD1) was shown to control gene expression and cell proliferation of androgen-dependent prostate cancer (PCa) cells, whereas the role of LSD1 in androgen-independent metastatic prostate cancer remains elusive. Here, we show that depletion of LSD1 leads to increased migration and invasion of androgen-independent PCa cells. Transcriptome and cistrome analyses reveal that LSD1 regulates expression of lysophosphatidic acid receptor 6 (LPAR6) and cytoskeletal genes including the focal adhesion adaptor protein paxillin (PXN). Enhanced LPAR6 signalling upon LSD1 depletion promotes migration with concomitant phosphorylation of PXN. In mice LPAR6 overexpression enhances, whereas knockdown of LPAR6 abolishes metastasis of androgen-independent PCa cells. Taken together, we uncover a novel mechanism of how LSD1 controls metastasis and identify LPAR6 as a promising therapeutic target to treat metastatic prostate cancer.

2017-04-25 | GSE57078 | GEO

Lysine-specific demethylase 1 metastasis of androgen-independent PCa cells [ChIP-seq]

2017-04-25 | GSE57077 | GEO

Effect of BMP4 overexpression in MycCaP cells on TAMs in ostegenic prostate tumors

Project description:Tumor-associated macrophages (TAMs) play an important role in cancer progression and have been implicated to play a role in prostate cancer. However, TAMs in osteogenic prostate cancer bone metastasis have not been characterized. Here we used a novel osteogenic MycCaP-BMP4 model to study the unique cellular and molecular mechanisms in driving the tumor progression in osteogenic prostate cancer metastasis.

2024-09-08 | GSE241344 | GEO

miR-33b-3p Suppresses Metastasis in Prostate Cancer by Targeting DOCK4

Project description:Purpose: Despite that androgen-deprivation therapy results in long-lasting responses, the disease inevitably progresses to metastatic castration-resistant prostate cancer. In this study, we identified miR-33b-3p as a suppressor of metastasis in prostate cancer. miR-33b-3p was significantly reduced in prostate cancer tissues, and the low expression of miR-33b-3p was correlated with poor overall survival of prostate cancer patients. Overexpression of miR-33b-3p inhibited both migration and invasion of highly metastatic prostate cancer cells whereas antagonizing miR-33b-3p promoted those processes in lowly metastatic cells. The in vivo results demonstrate that miR-33b-3p suppresses metastasis of tail vein inoculated prostate cancer cells to lung, liver, and lymph node in mice. DOCK4 was validated as the direct target of miR-33b-3p. miR-33b-3p decreased the expression of DOCK4 and restoration of DOCK4 could rescue miR-33b-3p inhibition on cell migration and invasion. Moreover, downregulation of miR-33b-3p was induced by bortezomib, the clinically used proteasome inhibitor, and overexpression of miR-33b-3p rescued the insufficient inhibition of bortezomib on migration and invasion in prostate cancer cells. Collectively, our findings demonstrate that miR-33b-3p suppresses metastasis by targeting DOCK4 in prostate cancer. Our results suggest that enhancing miR-33b-3p expression may provide a promising therapeutic strategy for overcoming that proteasome inhibitor’s poor efficacy against metastatic prostate cancer.

2021-09-08 | GSE183428 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data